BRAF and melanoma: These results are consistent with work by Baenke et al., which showed that melanomas with acquired resistance to BRAF inhibitors with High-OXPHOS switched from glucose to glutamine as their primary energy source.27 Excitingly, CB839, a novel small molecule glutaminase inhibitor currently being used in multiple clinical trials, improved survival as a single-agent in 2 different models of High-OXPHOS, MAPKi-resistant MBMs (A375-R1 and MEL624).